Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.62 |
| ▸ | GHSR | Q92847 | 5/20 | 0.62 |
| ▸ | NPY1R | P25929 | 3/20 | 0.59 |
| ▸ | NPY2R | P49146 | 3/20 | 0.59 |
| ▸ | NPY4R | P50391 | 3/20 | 0.59 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29706289 | 1.00 | KISS1R (0.62) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| SCHEMBL31404052 | 0.95 | GHSR (0.68) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| Acetic Acid SCHEMBL29757019 | 0.92 | IL23R (0.59) | UTS2R | |
| Acetic Acid SCHEMBL29377757 | 0.92 | IL23R (0.59) | UTS2R | |
| SCHEMBL29550957 | 0.91 | KISS1R (0.64) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| SCHEMBL29550946 | 0.91 | KISS1R (0.64) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| SCHEMBL30710492 | 0.91 | IL23R (0.59) | UTS2R | |
| SCHEMBL7103421 | 0.91 | IL23R (0.59) | UTS2R | |
| SCHEMBL14817785 | 0.91 | IL23R (0.59) | UTS2R | |
| SCHEMBL14509563 | 0.91 | GHSR (0.65) | KISS1RGHSRNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003749-A2 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | PREGLEM S.A. (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20110003749-A2 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | PREGLEM S.A. (CH) | 2011-01-06 | — | — | US | disclosed |
| US-20100152102-A1 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | PREGLEM S.A. (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152102-A1 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | PREGLEM S.A. (CH) | 2010-06-17 | — | — | US | disclosed |
| US-7648961-B2 | Accelerating the start of growth of quiescent follicles in non-menopausat women by administering somatostatin antagonist analog; reduces the risk of early menopause by preventing the accelerated activation of the follicular reserve which would make it more sensitive to chemotherapy agents or to radiation | PREGLEM S.A. (CH) | 2010-01-19 | — | — | US | disclosed |
| US-7648961-B2 | Accelerating the start of growth of quiescent follicles in non-menopausat women by administering somatostatin antagonist analog; reduces the risk of early menopause by preventing the accelerated activation of the follicular reserve which would make it more sensitive to chemotherapy agents or to radiation | PREGLEM S.A. (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20070155659-A1 | Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION (FR) | 2007-07-05 | — | — | US | disclosed |
| US-20070155659-A1 | Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION (FR) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152102-A1 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | FSHR, GNRHR, SSTR3 | KISS1R 22/4885GHSR 10/4885NPY1R 34/4885 |
| US-20070155659-A1 | Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women | FSHR, GNRHR, SSTR3 | KISS1R 22/4885GHSR 10/4885NPY1R 34/4885 |
| US-20110003749-A2 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN | FSHR, GNRHR, SSTR3 | KISS1R 22/4885GHSR 10/4885NPY1R 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.